EUCTR2021-006953-77-DK进行中(未招募)1 期
Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy - TEMPO II
Aarhus University Hospital0 个研究点目标入组 140 人开始时间: 2022年1月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Informed consent
- •- Age = 18 years
- •- Maximal wall thickness = 15 mm unrelated to hypertension, valve diseases or storage diseases.
- •- And one of the following:
- •1.New York Heart Association – functional class (NYHA) = II
- •2.A history of NYHA class = II before treatment with BB or CCB
- •3.pro-BNP>300 ng/l/35>nmol/l or BNP >100ng/l/>29nmol/l
- •4.Non-sustained VT (>120 min-1, =3 cycles) documented within the last 2 years of screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •- Left ventricular ejection fraction < 50%
- •- LVOT gradient >30 mmHg at rest or during Valsalva maneuver after discontinuation of BB or CCB respectively
- •- Previous history of LVOT gradient >30 mmHg at rest, during exercise or during Valsalva maneuver.
- •- Permanent atrial fibrillation
- •- Permanent right ventricular pacing
- •- Previous intolerance for Bisoprolol (BB) or Verapamil (CCB)
- •- Known present obstructive coronary disease (previous percutaneous coronary intervention is accepted)
- •- eGFR < 40 ml/min
- •- Fertile women (<50 years) who are pregnant (Positive Plasma-HCG), breastfeeding or not using anticonceptions.
- •- Significant liver failure, severe valvular disease, bradycardia (40bpm) or hypotension (systolic <100mmHg), other significant comorbidity or risks associated with discontinuation of BB or CCB after individual judgement by the investigators.
- •- Unable to understand patient information intellectually or linguistically
- •- Unable to perform exercise test.
- •- Unable to speak and/or understand Danish.
- •Additional exclusion criteria for CMRI sub-study:
- •- Implantable cardioverter defibrillator (any kind)
- •- Pacemaker (any kind)
- •- Metal implants like to affect image quality
- •- Metal implants that poses a risk during CMR
- •- Inability to cope with being in the scanner.
研究者
相似试验
进行中(未招募)
1 期
Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathyon-obstructive hypertrophic cardiomyopathyCTIS2024-515346-17-00Aarhus Universitetshospital140
招募中
4 期
Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic CardiomyopathyNCT05569382Morten Steen Kvistholm Jensen100
已完成
2 期
Evaluation of preventive effect of bisoprolol in sub clinical Heart failureIRCT20240609062050N1Iran University of Medical Sciences70
已完成
3 期
Evaluation of the effect of bisoprolol in the control of atrial fibrillatioAtrial fibrillation in patients undergoing coronary artery bypass grafting.Atrial fibrillation and flutterIRCT20210121050095N1Qazvin University of Medical Sciences114
已完成
不适用
Ivabradine in Prevention of POAF after CABG surgeryCardiologyPACTR202103543569729Faculty of Medicine University of Alexandria50
